<DOC>
	<DOCNO>NCT02808767</DOCNO>
	<brief_summary>This study evaluate efficacy Prasugrel Ticagrelor treatment acute myocardial infarction .</brief_summary>
	<brief_title>Comparison Prasugrel Ticagrelor Treatment Acute Myocardial Infarction</brief_title>
	<detailed_description>Study objective : 1 . Compare efficacy safety prasugrel ticagrelor acute myocardial infarction treat emergent PCI . 2 . Assess safety switch clopidogrel remission acute phase MI patient economic barrier allow continue treatment prasugrel ticagrelor . All randomized patient acute myocardial infarction treat standard therapeutic procedure accordance guideline European Society Cardiology ( ESC ) . Participation patient study connect deviation ESC guideline recommendation .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Acute myocardial infarction ( &gt; 1mm ST elevation least 2 related lead ST depression &gt; 2mm 3 lead new BBB ) indication emergent ( within 120 minut admission PCI center ) coronary angiography PCI , 2 . Signed informed consent . 1 . History stroke , 2 . Serious bleed within last 6 month , 3 . Indication oral anticoagulation ( e.g . atrial fibrillation , artificial valve , thromboembolism etc ... ) 4 . Use â‰¥ 300 mg clopidogrel another antiplatelet agent ( except aspirin low dose clopidogrel ) randomization , 5 . Low body weight ( &lt; 60 kg ) old patient ( &gt; 75 year age ) , 6 . Moderate severe liver dysfunction , 7 . Ongoing therapy strong CYP3A4 inhibitor ( e.g . ketoconazole , clarythromycine , nefazodone , ritonavir , atazanavit ) , 8 . Hypersensitivity prasugrel ticagrelor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Primary coronary intervention</keyword>
	<keyword>Antiplatelet therapy</keyword>
</DOC>